Attovia Therapeutics
Jin Wook Choi has a strong background in chemical and biochemical engineering, holding a Ph.D. and a Master's degree from UC Irvine. With extensive experience in the field, Jin Wook Choi has worked in various research positions at prestigious institutions such as Attovia Therapeutics, Alamar Biosciences, Inc., and UC Davis. Currently serving as a Sr. Scientist at Attovia Therapeutics, Jin Wook Choi specializes in VHH/Attobody discovery and engineering for therapeutic applications.
Attovia Therapeutics
Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.